Gilead's Trodelvy (sacituzumab govitecan-hziy) was approved by FDA for two indications, including as a first-line treatment for adult patients with unresectable locally advanced or metastatic triple-negative breast cancer (TNBC) who are not candidates for PD-1 or PD-L1 inhibitor-based therapy
It delivers 4 grams of non-GMO prebiotic FOS fiber, two clinically studied probiotic strains (DE111 and SNZ 1969), and 100% Daily Value of Vitamin D3 per serving -- with no added sugar, no gelatin, and no synthetic dyes
Early findings highlight its potential ability to: Protect the mucosal lining Reduce inflammation markers Support vascular and tissue recovery But outcomes vary, and human studies are still ongoing
The Triple-Agonist Revolution: Retatrutide and the Paradigm Shift in Multi-Hormonal Pharmacotherapy for Obesity and Cardiometabolic Comorbidities
In fact, genes related to adaptive immune system were up- regulated in M + Fc-GLP-1 mice post-PH (Supplementary Fig